Medipharm Labs Corp T.LABS

TD Bank gives a current book value of $0.20 for LABS !! :)

[1hot-techwoman]

People giving away there shares at $0.07 SMH :)

Medipharm Labs Corp does not pay a dividend.
Beta	1.16
EPS	$-0.05
Book Value	$0.20

[subaru1i]

In the world of currency trading there is a mechanism by which that market maintains efficiency and that is by way of 'arbitrage' trading.   That also applies here in this example where one of the largest banks in Canada values LABS at $.20 while we the collared stock price by algorithm trading sits at $.07.   Easy math says that's nearly a 200% gain and logic says

[srtman03]

Sure looks undervalued to me at this level with the amount of cash on hand !!!

[1hot-techwoman]

I Would,t think its time to be selling , lets say that !! :)

[Redwine12345]

Maybe you should. :). Check VPH. I am not promoting it. Until I see breakout, nothing to buy, nothing to sell.

[subaru1i]

Redwine, you realize waiting until you see a 'breakout' might be too late for a couple of reasons.  With smart phones and apps, news travels and is dissipated extremely more quickly than 20 years ago giving you much less response time to news.  The other factor you should seriously take into consideration is if someone like Pfizer simply takes an equity position in LABS to

[Redwine12345]

Subaru, this stock was going down from Apr 2019 to April-2022. It is going sideways almost 2 years. Sure you can buy at seven cents and wait for who knows how long with hope that it will open one day at $2.  It might happen. They keep price of this stock at this level for a reason. I am sure they are using programs to control the price. Calling "our parners" and not naming them

[subaru1i]

 I understand your logic of argument but also I want to temper that with a fact of this industry segment echoing what the CEO said.  Because we are in the pharmaceutical/human health care segment, things take longer because they involve clinical trials, 3 stages, the last involving humans and then waiting for approval once all of the data has been reviewed by the governing approval body